GCTK.NASDAQGlucotrack, INC
10-Q: GlucoTrack Inc. Reports Q3 2024 Results, Focuses on Implantable CGM Development
Sentiment:
Quarterly Report
GlucoTrack Inc. reported a net loss of $5.1 million for the third quarter of 2024, as it continues to develop its implantable continuous glucose monitor (CGM) technology.
Capital raiseThe company completed a public offering on November 14, 2024, raising gross proceeds of $10 million.The company plans to finance its operations through the sale of equity securities and/or debt securities.The company has entered into private placement agreements to raise additional capital.
Worse than expectedThe company's net loss has increased significantly compared to the same periods in the previous year.Operating expenses have risen substantially, indicating increased spending without corresponding revenue generation.The company's cash position has weakened, raising concerns about its ability to fund ongoing operations.
Summary
- GlucoTrack Inc. reported a net loss of $5.1 million for the three months ended September 30, 2024, compared to a net loss of $2.2 million for the same period in 2023.
- The company's operating expenses increased to $3.3 million in Q3 2024 from $2.2 million in Q3 2023, driven by higher research and development, marketing, and general and administrative costs.
- For the nine months ended September 30, 2024, the net loss was $12.5 million, compared to $4.7 million for the same period in 2023.
- Research and development expenses were $7.8 million for the nine months ended September 30, 2024, up from $3.0 million in the prior year period.
- The company's cash and cash equivalents stood at $346,000 as of September 30, 2024, with an additional $8.873 million expected from a public offering closing on November 14, 2024.
- GlucoTrack is focused on developing an implantable continuous glucose monitor (CGM) and has completed several animal studies demonstrating the feasibility of the technology.
- The company has made a regulatory submission for a first-in-human study, expected to begin in Q4 2024, and is also preparing for a long-term clinical trial expected to begin in late Q2 2025.
- GlucoTrack is working towards ISO13485 certification, with the second audit scheduled for December 2024.
Sentiment
Score: 3
Explanation: The document indicates a concerning financial situation with increasing losses and a weak cash position. While there is progress in technology development, the company's ability to continue as a going concern is in question, leading to a negative sentiment.
Positives
- The company is making progress in the development of its implantable CGM technology, with successful animal studies and a regulatory submission for a first-in-human study.
- GlucoTrack has a strong management team with experience in the medical device and diabetes industries.
- The company is working towards ISO13485 certification, which is an internationally recognized standard for medical device quality systems.
- The company has secured additional funding through a public offering in November 2024.
Negatives
- The company's net loss has increased significantly in both the three and nine-month periods ended September 30, 2024.
- Operating expenses have increased substantially, driven by higher research and development, marketing, and general and administrative costs.
- The company has a limited cash balance of $346,000 as of September 30, 2024, and is dependent on external sources for financing its operations.
- The company has incurred an accumulated deficit of $122.356 million.
- The company's disclosure controls and procedures are deemed ineffective due to material weaknesses in internal control over financial reporting.
Risks
- The company is dependent on external sources for financing its operations and may not be able to obtain the necessary funding.
- The company has a history of losses and negative cash flow and may not achieve profitability.
- The company's implantable CGM technology is still under development and may not be successful.
- The company relies on third parties for manufacturing and may experience supply chain issues.
- The company's common stock may be delisted from Nasdaq if it fails to maintain compliance with listing requirements.
- The company's disclosure controls and procedures are ineffective due to material weaknesses in internal control over financial reporting.
Future Outlook
The company expects research and development expenses to increase in 2025 and beyond, primarily due to hiring additional personnel and clinical trials for the Glucotrack CBGM. The company plans to finance its operations through the sale of equity and/or debt securities.
Management Comments
- Management has considered the significance of the company's financial condition and determined that these conditions raise substantial doubt about the company's ability to continue as a going concern.
- The company intends to continue to invest in its talent and to expand and strengthen all areas within the company.
Industry Context
The company is operating in the competitive diabetes technology market, which is seeing a shift towards continuous glucose monitoring (CGM) solutions. The company's focus on implantable CGM technology aligns with this trend, but it faces competition from established players and other emerging companies in the space.
Comparison to Industry Standards
- Dexcom and Abbott are established leaders in the CGM market, with products like the Dexcom G7 and Abbott FreeStyle Libre series, which are non-implantable.
- Senseonics is a competitor in the implantable CGM space with its Eversense product, which has a longer sensor life than traditional CGMs but requires a removal and replacement procedure.
- GlucoTrack's implantable CGM is aiming for a longer implant life of at least two years, potentially offering a competitive advantage over existing solutions.
- The company's technology is still in the development phase, and its success will depend on the results of clinical trials and regulatory approvals.
- The company's financial results are not directly comparable to established players due to its early stage of development and lack of commercialized products.
Related Party Transactions
- The company entered into a private placement agreement with certain members of its executive management, Board of Directors and existing shareholders.
- The company entered into a series of convertible promissory notes with three directors, and one member of the company's executive management.
Stakeholder Impact
- Shareholders are at risk due to the company's financial instability and potential delisting from Nasdaq.
- Employees may be affected by potential cost-cutting measures or restructuring.
- Customers may be impacted by delays in product development or commercialization.
- Suppliers and creditors may face increased risk due to the company's financial challenges.
Next Steps
- The company expects to initiate a first-in-human study in Q4 2024, pending regulatory approval.
- The company is preparing for a long-term clinical trial expected to begin in late Q2 2025.
- The company is working towards ISO13485 certification, with the second audit scheduled for December 2024.
Key Dates
| Date | Description |
|---|---|
| 2004-03-03 | Date of Israeli Innovation Authority grant to Integrity Israel. |
| 2004-03-04 | Date of Israeli Innovation Authority grant to Integrity Israel. |
| 2022-10-07 | Date of Intellectual Property Purchase Agreement with Paul Goode. |
| 2023-01-01 | Start of the period for financial comparisons. |
| 2023-06-01 | Date of first performance milestone achievement related to the Intellectual Property Purchase Agreement. |
| 2023-06-20 | Date of first performance milestone achievement related to the Intellectual Property Purchase Agreement. |
| 2023-07-01 | Start of the period for financial comparisons. |
| 2023-09-30 | End of the period for financial comparisons. |
| 2023-12-31 | End of the fiscal year for financial comparisons. |
| 2024-01-01 | Start of the period for financial comparisons. |
| 2024-01-03 | Exercise of pre-funded warrants. |
| 2024-02-13 | Date of Exchange Agreement with certain warrant holders. |
| 2024-02-19 | Date of Lease Agreement with Tapsak Enterprises LLC. |
| 2024-04-22 | Date of private placement agreement. |
| 2024-04-26 | Date of Annual Meeting of Shareholders. |
| 2024-04-30 | Date of reverse stock split approval by the Board of Directors. |
| 2024-05-01 | Date of second performance milestone achievement related to the Intellectual Property Purchase Agreement. |
| 2024-05-17 | Date of filing of Certificate of Amendment for reverse stock split. |
| 2024-05-31 | Date of second performance milestone achievement related to the Intellectual Property Purchase Agreement. |
| 2024-06-27 | Date of note and warrant purchase agreements with certain investors. |
| 2024-06-30 | End of the period for financial comparisons. |
| 2024-07-01 | Closing date of the private placement of unsecured promissory notes and warrants. |
| 2024-07-18 | Date of convertible promissory notes with certain investors. |
| 2024-07-30 | Date of convertible promissory note and warrant agreements with an existing investor. |
| 2024-08-23 | Date of conversion agreement with two of the June 27 Investors. |
| 2024-09-05 | Date of conversion agreement with one of the June 27 Investors and July 18 Investors. |
| 2024-09-24 | Date of special meeting of stockholders approving the conversion of the July 30 Note. |
| 2024-09-30 | End of the reporting period for the quarterly report. |
| 2024-10-15 | Date of issuance of shares for conversion agreements. |
| 2024-11-03 | Date of outstanding shares of the company. |
| 2024-11-12 | Date of completion of public offering. |
| 2024-11-14 | Closing date of the public offering. |
Keywords
Implantable CGM, Continuous Glucose Monitoring, Medical Device, Diabetes, Clinical Trials, ISO13485, Regulatory Approval, Financial Results, Research and Development, Public Offering
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.